Peptable

Comparison

Exenatide vs LL-37

Function

While Exenatide is used for type 2 diabetes treatment to improve glycemic control and modestly reduce body weight through GLP-1–like insulinotropic and glucagonostatic effects6768, LL-37 acts as a broad-spectrum antimicrobial and immunomodulatory peptide involved in host defense and wound repair, but can also promote inflammation and cancer cell proliferation in some contexts5215.

Mechanism

While Exenatide works as a 39-amino-acid exendin-4 peptide originally isolated from Gila monster venom that acts as a long-acting GLP-1 receptor agonist resistant to DPP-4 degradation67, LL-37 is a cationic amphipathic 37-amino-acid cathelicidin peptide generated from hCAP18 that disrupts microbial membranes and modulates innate immunity, including chemotaxis, cytokine induction, and NET formation521586.

Receptor

Exenatide

GLP-1 receptor (GLP1R) 6780

LL-37

Functions as a ligand for CXCR2 on neutrophils and other myeloid cells; LL-37 signaling has also been linked to FPR2 and P2X7 in various cell types515

Organism or Origin

Exenatide

Originally from Heloderma suspectum (Gila monster) venom; now produced synthetically67

LL-37

Human cathelicidin antimicrobial peptide generated from the CAP-18 precursor5286

Gene

Exenatide

Not assigned in the current dataset.

LL-37

CAMP

Summary

Exenatide and LL-37 are noticeably different, with limited direct overlap in their usual biological context. Their typical research and application settings separate fairly clearly: Exenatide is more often discussed in the realm of Metabolic and endocrine, whereas LL-37 is more often associated with the realm of Immunology and inflammation and Gastroenterology. They also influence different molecular systems, with Exenatide tracking more closely to GLP-1 receptor while LL-37 centers more on GPCR receptor. Exenatide has a more venom-derived origin, while LL-37 is closer to natural endogenous background and their development context also differs, with Exenatide approved while LL-37 is in Preclinical development. Exenatide incorporates amidation features that are not part of LL-37.

Sources

67Exendin 4 – Potent GLP-1R agonist - SB PEPTIDE, https://www.sb-peptide.com/project/exendin-4-potent-glp-1r-agonist/
68Glucagon-like peptide-1 analogues: An overview - PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC3712370/
80GLP-1 Localisation and Proglucagon Gene Expression in ..., https://pmc.ncbi.nlm.nih.gov/articles/PMC6200298/
52Cathelicidin LL-37: A new important molecule in the ... - PMC - NIH, https://pmc.ncbi.nlm.nih.gov/articles/PMC7388365/
86Cathelicidin antimicrobial peptide - Wikipedia, https://en.wikipedia.org/wiki/Cathelicidin_antimicrobial_peptide